SCHEMBL3699237

SCHEMBL3699237

Cc1c(Cl)cccc1NC(=O)Nc1cccc2c1ccn2Cc1c[nH]c2ncccc12

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
TRPV1 Q8NER1 1/20 0.45
POLB P06746 2/20 0.41
MEN1 O00255 1/20 0.40
RAB9A P51151 1/20 0.40
MTNR1A P48039 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
DRD4 P21917 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
TP53 P04637 1/20 0.39
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3705143 0.92 HTT (0.46) KMT2APOLBMEN1RAB9AMTNR1A
Hydrochloric Acid SCHEMBL3697923 0.91 HTT (0.45) KMT2APOLBMEN1RAB9AMTNR1A
SCHEMBL3704922 0.90 HTR1A (0.42) KMT2AMEN1RAB9AMTNR1ASMN1; SMN2
SCHEMBL3695287 0.89 MTNR1A (0.39) MTNR1AALDH1A1DRD4KDM4EHPGD
SCHEMBL3709520 0.89 PTGER3 (0.40) POLBMTNR1AALDH1A1DRD4KDM4E
SCHEMBL3699011 0.88 ALDH1A1 (0.45) KMT2APOLBMEN1RAB9AMTNR1A
SCHEMBL3701969 0.88 JAK2 (0.45) KMT2ATRPV1POLBMEN1RAB9A
Hydrochloric Acid SCHEMBL3706766 0.87 ALDH1A1 (0.44) KMT2APOLBMEN1RAB9AMTNR1A
SCHEMBL27807485 0.87 TRPV1 (0.48) TRPV1POLBSMN1; SMN2MAPTHTT
SCHEMBL3710294 0.87 PTGER3 (0.42) KMT2APOLBMEN1RAB9AMTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648086-B2 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors ASCEPION PHARMACEUTICALS, INC. (CN) 2014-02-11 US claimed
US-20120122895-A1 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS JIANG, SHAN 2012-05-17 US claimed
US-8648086-B2 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors ASCEPION PHARMACEUTICALS, INC. (CN) 2014-02-11 US disclosed
US-20120122895-A1 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS JIANG, SHAN 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122895-A1 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS FLT3, CSF1R, EPHA2 KMT2A 1244/4885TRPV1 4841/4885POLB 3719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.